Educational Symposium

Improving Outcomes in Secondary Hyperparathyroidism

November 07, 2019 | 12:45 PM - 01:45 PM

Location: TBD 1, Marriott Marquis

Session Description

Secondary hyperparathyroidism (SHPT) develops early in the course of CKD before the initiation of dialysis and escalates as kidney function declines toward stage 5 CKD. Uncontrolled SHPT is associated with elevated levels of calcium, phosphorus, and fibroblast growth factor 23, each of which are independently associated with increased morbidity and mortality. Therefore, early diagnosis and management of SHPT in patients with CKD are important to retard disease progression as well as reduce morbidity and mortality. Recent advances in SHPT research have shown that the calcium-sensing receptor (CaSR) is a principal regulator of PTH and consequently calcium and phosphorus levels. Calcimimetic agents modulate CaSR sensitivity to calcium and reduce PTH secretion and may provide better control of SHPT than conventional therapies. However, despite advances in developing calcimimetic drugs, control of SHPT remains a challenge.

This activity is supported by educational funding provided by Amgen.

Learning Objective(s)

  • Describe the role of both oral and IV calcimimetics in achieving goals in the treatment of SHPT
  • Describe the potential advantages of an IV calcimimetic in the management of patients with SHPT

Learning Pathway(s)

  • Chronic Kidney Disease

Moderator

  • Sana F. Khan, MD

Presentations

  • Introduction
    12:45 PM - 12:55 PM
    Sana F. Khan, MD
  • The Biology of the Calcium-Sensing Receptor and Its Role in SHPT
    12:55 PM - 01:15 PM
    Holly J. Kramer, MD, MPH
  • Managing Hyperparathyroidism in Hemodialysis: The Role of Calcimimetics
    01:15 PM - 01:35 PM
    Kevin J. Martin, MD, FASN
  • Questions and Answers
    01:35 PM - 01:45 PM